Journal Mobile Options
Table of Contents
Vol. 60, No. 1, 2009
Issue release date: September 2009
Neuropsychobiology 2009;60:44–48

Blind Verification of Elevated Platelet Autoantibodies in Serum of Schizophrenic Patients – Part I: Young Subjects

Spivak B. · Schechtman M. · Blumensohn R. · Schönherz-Pine Y. · Yoran-Hegesh R. · Deckmann M. · Mayer R. · Weizman A. · Shinitzky M.
aBeer Yaakov-Ness Ziona Mental Health Center, Beer Yaakov, bDepartment of Psychiatry, Sackler Faculty of Medicine, Tel Aviv University, cNeurogenic, Tel Aviv, dDepartment of Biological Chemistry, The Weizmann Institute of Science, Rehovot, eGeha Mental Health Center, and fLaboratory of Biological Psychiatry, Felsenstein Medical Research Center, Beilinson Campus, Petah Tikva, Israel

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: It has been hypothesized that the etiology of schizophrenia, in a distinct group of patients, originates from an autoimmune reaction against platelets. Previous open screenings have recorded significantly higher blood titers of platelet-associated autoantibodies (PAA) in schizophrenic patients as compared to normal healthy subjects. In addition, young schizophrenic patients at the early stages of their disorder displayed higher PAA titers than older patients with a longer duration of the disorder. A blood test based on these observations was proposed. Aim: To verify by a blind test a significant difference in PAA between young schizophrenic patients and matched healthy control subjects, for the validation of a blood test for schizophrenia. Methods: A total of 36 young schizophrenic patients in an active psychotic state, aged 13–20 years (mean ± SD: 16.2 ± 2.1 years) with an average PANSS score of 115.6 ± 14.5 and illness duration of 9.5 ± 9.4 months, were examined. The control group consisted of 49 healthy young subjects between the ages of 13 and 21 years (16.2 ± 2.2 years). The blood titers of PAA were evaluated blindly using an optimized ELISA test, expressed by a linear optical density (OD) scale. The blood samples of all participants were tested anonymously, and were scored under a code number. A test recording above 1.3 OD units was defined as positive. Results: The PAA titers of schizophrenia patients (1.6 ± 0.4 OD units, range: 0.7–2.3 OD units) were significantly higher than those of the control group (1.0 ± 0.4 OD units, range: 0.4–1.8 OD units; p < 0.0001). In 61% of the young schizophrenic patients (22 out of the 36 patients), a positive result (OD >1.3 units) was recorded. In the control group, only 12.2% (6 of the 49 subjects) displayed a positive result (p < 0.0001). Conclusions: These findings support further assessment of PAA titers as a potential biomarker for patients with clinical signs and symptoms of schizophrenia.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 1994.
  2. Freedman R: Schizophrenia. New Engl J Med 2003;349:1738–1749.
  3. Rupp A, Keith SJ: The costs of schizophrenia: assessing the burden. Psychiatr Clin North Am 1993;16:413–423.
  4. Jones AL, Mowry BJ, Pender MP, Greer JM: Immune dysregulation and self-reactivity in schizophrenia: do some cases of schizophrenia have an autoimmune basis? Immunol Cell Biol 2005;83:9–17.
  5. Knight JG, Menkes DB, Highton J, Adams DD: Rationale for a trial of immunosuppressive therapy in acute schizophrenia. Mol Psychiatry 2007;12:424–431.
  6. Strous RD, Shoenfeld Y: Schizophrenia, autoimmunity and immune system dysregulation: a comprehensive model updated and revisited. J Autoimmun 2006;27:71–80.
  7. Shinitzky M, Deckmann M, Kessler A, Sirota P, Rabbs A, Elizur A: Platelet autoantibodies in dementia and schizophrenia-possible implication for mental disorders. Ann NY Acad Sci 1991;621:205–217.
  8. Kessler A, Shinitzky M: Platelets from schizophrenic patients bear autoimmune antibodies that inhibit dopamine uptake. Psychobiology 1993;21:299–306.
  9. Deckmann M, Shinitzky M, Leykin I, Cheng D, Guy J, Sirota P, et al: Humoral and cellular response against autologous platelets. Ital J Psych Behav Sci 1996;6:29–34.
  10. Schwarz MJ, Ackenheil M, Riedel M, Muller N: Blood-cerebrospinal fluid barrier impairment as indicator for an immune process in schizophrenia. Neurosci Lett 1998;253:201–203.
  11. Shinitzky M, Leykin I, Deckmann M: Autoimmunity against platelets in schizophrenia; in The Decade of Autoimmunity. Amsterdam, Elsevier, 1999, pp 277–284.
  12. Deckmann M, Mamillapalli R, Schechtman L, Shinitzky M: A conformational epitope which detects autoantibodies from schizophrenic patients. Clinica Chemica Acta 2002;322:91–98.
  13. First MB, Spitzer RL, Gibbon M, et al: Structured Clinical Interview for Axis I DSM-IV Disorders, Patient Version (SCID-I/P), Version 2. New York, New York State Psychiatric Institute Biometrics Research Department, 1995.
  14. Kay S, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale for schizophrenia. Schizophr Bull 1987;13:261–276.
  15. Schwarz M, Spector L, Gortler M, et al: Serum anti-Glc(α1,4)Glc(α) antibodies as a biomarker for relapsing-remitting multiple sclerosis. J Neurol Sci 2006;244:59–68.
  16. Spivak B, Schechtman M, Blumensohn R, Schönherz-Pine Y, Yoran-Hegesh R, Deckmann M, Mayer R, Weizman A, Shinitzky M: Blind verification of elevated platelet autoantibodies in serum of schizophrenic patients. Part II. Adult subjects. Neuropsychobiology 2009;60:49–54.
  17. Aster AH, Bougie D: Drug-induced immune thrombocytopenia. New Engl J Med 2007;357:580–587.
  18. George JN, Raskob GE, Shah SR, Rizvi MA, Hamilton SA, Osborne S, Vondracek T: Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med 1998;129:886–890.
  19. Levine J, Susnovski M, Handzel Z, Leykin I, Shinitzky M: Treatment of schizophrenia with an immunosuppressant. Lancet 1994;344:59–60.
  20. Canoso RT, deOliviera RM, Nixon RA: Neuroleptic-associated autoantibodies: a prevalence study. Biol Psychiatry 1990;27:863–870.
  21. Lillicap DP, Pinto M, Benford K, Ford PM, Ford S: Heterogenicity of laboratory test results for antiphospholipid antibodies in patients treated with chloropromazine and other phenothiazines. Am J Clin Pathol 1990;93:771–775.

    External Resources

  22. Schwartz M, Silver H: Lymphocytes, autoantibodies and psychosis – coincidence versus etiological factors: an update. Isr J Psychiatry Relat Sci 2000;37:32–36.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50